CKD-FIX: A Randomised, Controlled Trial Of Allopurinol In The Slowing Of Kidney Disease Progression
Funder
National Health and Medical Research Council
Funding Amount
$1,917,147.00
Summary
Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.
Modulating Inflammatory And Fibrogenic Pathways In Kidney Disease Using A Novel Antagonist Of Protease-Activated-Receptor-2
Funder
National Health and Medical Research Council
Funding Amount
$581,116.00
Summary
Chronic kidney disease (CKD) now affects 10% of adults in industrialised countries. Current treatments are largely ineffective. Thus developing better CKD treatments will have substantial public health benefit. Three well established and clinically relevant animal models of kidney disease will be used to test the ability of a new experimental anti-inflammatory drug, developed by members of this research team at The University of Queensland, to prevent or lessen the progression of CKD.
Chronic Kidney Disease Centre Of Research Excellence
Funder
National Health and Medical Research Council
Funding Amount
$2,606,487.00
Summary
The Chronic Kidney Disease Centre of Research Excellence (CKD.CRE) is an Australian first, dedicated to the improvement of CKD knowledge and management across the health care spectrum. With five research streams, the CKD.CRE will establish a national surveillance network, support improved detection in primary care, inform on renal supportive care and on rationalised resource utilisation. In addition, the CKD.CRE will conduct biomarker research and will establish Australia’s first CKD BioBank.
SGLT2 inhibitors are new glucose-lowering agents for type 2 diabetes. They promote glucose loss into urine, which lowers blood glucose levels. However, little is known regarding the changes to kidney physiology when this system is manipulated with these drugs. There is evidence that SGLT2 inhibitors do not protect against kidney disease in diabetic mice, despite being an effective blood glucose-lowering agent. I aim to characterise the changes to kidney function upon SGLT2 blockade in diabetes.
Telerehabilitation: Assessing Acquired Neurogenic Communication Disorders Online.
Funder
National Health and Medical Research Council
Funding Amount
$172,446.00
Summary
People who suffer brain damage as a result of a stroke, head injury, or a disorder such as Parkinson's disease frequently develop difficulty in either speaking, writing, reading, or understanding the spoken language. As a result, the person's ability to communicate with his or her family and friends, and the community in general is seriously affected. Individuals who experience these speech and language disorders are treated by a speech pathologist who focuses on improving the person's ability t ....People who suffer brain damage as a result of a stroke, head injury, or a disorder such as Parkinson's disease frequently develop difficulty in either speaking, writing, reading, or understanding the spoken language. As a result, the person's ability to communicate with his or her family and friends, and the community in general is seriously affected. Individuals who experience these speech and language disorders are treated by a speech pathologist who focuses on improving the person's ability to communicate. The treatment of these disorders is frequently long-term requiring speech pathology management beyond existing hospital care. For many people with these communication disorders, accessing speech pathology services after their discharge from hospital may be very difficult due to their physical difficulties, the distances they are required to travel, and the limited availability of speech pathologists in their local community. This project aims to overcome these access issues through the development of a telerehabilitation system that will enable speech pathologists to assess people with these speech and language difficulties across the Internet using videoconferencing. It is intended that this research will ultimately enable people with these types of communication difficulties to be assessed and treated within their own home or local community.Read moreRead less